OTCMKTS:MVRBF Medivir AB (publ) (MVRBF) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free MVRBF Stock Alerts $0.82 0.00 (0.00%) (As of 06/15/2023) Add Compare Share Share Today's Range$0.82▼$0.8250-Day Range$0.82▼$0.8252-Week Range$0.68▼$0.82VolumeN/AAverage Volume925 shsMarket CapitalizationN/AP/E Ratio0.03Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Medivir AB (publ) alerts: Email Address Ad Chaikin AnalyticsMy system predicted the BA collapse – now it’s issuing an AI warningEven after several plane crashes and equipment malfunctions... a congressional hearing... and the worst PR firestorm in recent memory... The FTC's commission chair Lina Khan still deems Boeing (BA), "too big to fail" Click to see why a similar situation is currently brewing in the AI market... About Medivir AB (publ) Stock (OTCMKTS:MVRBF)Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.Read More MVRBF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MVRBF Stock News HeadlinesFebruary 26, 2024 | prnewswire.comChange in Medivir's nomination committee before the 2024 AGMSee More Headlines Receive MVRBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medivir AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:MVRBF CUSIPN/A CIKN/A Webwww.medivir.com Phone(685) 468-3100FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.03 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Jens Lindberg (Age 52)Chief Exec. Officer Mr. Magnus Christensen (Age 49)Chief Financial Officer Mr. Fredrik Öberg (Age 58)Chief Scientific Officer & Chief Medical Officer Ms. Pia Baumann (Age 57)Chief Medical Officer Karin TunbladSr. Principal Scientist & MIV-818 Project LeaderKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors MVRBF Stock Analysis - Frequently Asked Questions How have MVRBF shares performed in 2024? Medivir AB (publ)'s stock was trading at $0.82 at the start of the year. Since then, MVRBF stock has increased by 0.0% and is now trading at $0.82. View the best growth stocks for 2024 here. How do I buy shares of Medivir AB (publ)? Shares of MVRBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MVRBF) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medivir AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.